(NYSEMKT: AEON) Aeon Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.96%.
Aeon Biopharma's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast AEON's revenue for 2025 to be $44,590,852, with the lowest AEON revenue forecast at $44,590,852, and the highest AEON revenue forecast at $44,590,852. On average, 1 Wall Street analysts forecast AEON's revenue for 2026 to be $615,958,385, with the lowest AEON revenue forecast at $615,958,385, and the highest AEON revenue forecast at $615,958,385.
In 2027, AEON is forecast to generate $5,367,151,502 in revenue, with the lowest revenue forecast at $5,367,151,502 and the highest revenue forecast at $5,367,151,502.